Article citationsMore>>

Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. (2014) Efficacy and Safety of Empagliflozin Added to Existing Antidiabetes Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. The Lancet Diabetes & Endocrinology, 2, 369-384.
https://doi.org/10.1016/s2213-8587(13)70208-0

has been cited by the following article:

• TITLE: SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM

  AUTHORS: Rushi Patel, Terry Oroszi

  KEYWORDS: SGLT-2 Inhibitors, Type 2 Diabetes Mellitus, Cardiovascular Outcomes, Renal Protection, Glycemic Control

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.15 No.12, December 30, 2024

  ABSTRACT: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.